Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Aytu Biopharma (AYTU) over the last 12 years, with Q4 2025 value amounting to $6.0 million.

  • Aytu Biopharma's Cost of Revenue rose 1035.88% to $6.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.7 million, marking a year-over-year decrease of 55.33%. This contributed to the annual value of $20.9 million for FY2025, which is 532.99% down from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Cost of Revenue is $6.0 million, which was up 1035.88% from $5.3 million recorded in Q3 2025.
  • Aytu Biopharma's Cost of Revenue's 5-year high stood at $13.9 million during Q1 2021, with a 5-year trough of $4.8 million in Q2 2025.
  • Moreover, its 5-year median value for Cost of Revenue was $7.0 million (2023), whereas its average is $8.3 million.
  • As far as peak fluctuations go, Aytu Biopharma's Cost of Revenue soared by 59721.75% in 2021, and later plummeted by 5820.06% in 2024.
  • Over the past 5 years, Aytu Biopharma's Cost of Revenue (Quarter) stood at $10.8 million in 2021, then dropped by 2.46% to $10.6 million in 2022, then crashed by 50.59% to $5.2 million in 2023, then rose by 4.16% to $5.4 million in 2024, then rose by 10.36% to $6.0 million in 2025.
  • Its Cost of Revenue stands at $6.0 million for Q4 2025, versus $5.3 million for Q3 2025 and $4.8 million for Q2 2025.